{"name":"Birch BioMed Inc","slug":"birch-biomed-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxONEdpdjUzMmhaV2M1ek5nU0tDNjBkMGJGaWxMREEyaTlwczk5SEhNX21UcDdJYmRpSTRZb2R3bzY0S2hkLU41Y1Z4T1EweTRpY1FjYzBMeUpFdmVfZWlzbTZRNlZoZHlqRG1CTXN0YldDcHdjdWU2czE4TVctV2Y1Z1ZHT1pYM3NwX0xOQXU4WkdQNXd0TUdWRmlCSEk5VnRRc3E2a3dOX2pfYjd5cW5PTjIzYlVmOEY4UVlSS1FLOVNMMlRiMXdz?oc=5","date":"2026-02-04","type":"regulatory","source":"newswire.ca","summary":"BirchBioMed Receives Health Canada Approval for Topical Cream (NPN 80147114) - newswire.ca","headline":"BirchBioMed Receives Health Canada Approval for Topical Cream (NPN 80147114)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNb1Z4dkNOSkI2cGdOaGhOaHZZMmxVUUNodURBSW04TkppTkNUaVhkc2NwTjRfbVNCcWZudHlTbHhXR01CTVU2UTY5ZDIwbGRzSjd2UWt1dWstNTk0bVZoaDM1bWFzR0Q1RlNyLUFVTklOem5BSlRRWUN3akNWOFVyQW5NSGZzbEs0N01kZWRUM01FMTlaXzJlcGROM0JkeWJkTmhtN2xjT2ozZXVNUnFad0NOdmg5eENMSEhRblY3TG0xYkpQTnRIOExZSGQzNkRLbFp6d0EteEU0b1lDODBLSlBGVWIzZkhHbDMzUTVIU2hKYVk?oc=5","date":"2025-12-02","type":"regulatory","source":"newswire.ca","summary":"U.S. FDA GRANTS BIRCHBIOMED ORPHAN DRUG DESIGNATION FOR FS2 IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS - newswire.ca","headline":"U.S. FDA GRANTS BIRCHBIOMED ORPHAN DRUG DESIGNATION FOR FS2 IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}